论文部分内容阅读
目的观察术前新辅助化疗治疗进展期胃癌的临床疗效。方法选择医院2014年10月-2016年9月收治的进展期胃癌患者78例,按入院单双号顺序将其分为2组各39例。研究组术前接受新辅助化疗方案:氟尿嘧啶和亚叶酸钙、奥沙利铂联合化疗,对照组接受单纯手术治疗,比较2组患者近期治疗效果和不良反应。结果研究组总有效率为76.92%高于对照组的51.28%,不良反应发生率为15.38%低于对照组的28.21%,差异均有统计学意义(P<0.05)。结论术前新辅助化疗治疗进展期胃癌能够明显提高患者手术切除率,不良反应少,提高了临床疗效及患者生活质量,延长了患者生存期,值得临床应用并推广。
Objective To observe the clinical effect of preoperative neoadjuvant chemotherapy for advanced gastric cancer. Methods Seventy-eight patients with advanced gastric cancer admitted from October 2014 to September 2016 in our hospital were divided into two groups (39 cases) according to the order of hospital admission. The study group received neoadjuvant chemotherapy before surgery: fluorouracil and leucovorin, oxaliplatin combined with chemotherapy, and the control group received simple surgical treatment. The recent treatment and adverse reactions were compared between the two groups. Results The total effective rate was 76.92% in the study group, 51.28% in the control group and 15.38% in the control group, which was significantly lower than that in the control group (28.21%, P <0.05). Conclusion Preoperative neoadjuvant chemotherapy for advanced gastric cancer can significantly improve the surgical resection rate, fewer adverse reactions, improve clinical efficacy and quality of life of patients, prolonging the survival of patients, it is worthy of clinical application and promotion.